[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531496":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":11,"studyPopulation":38,"armGroups":39,"interventions":11,"overallOfficials":11,"centralContacts":47,"locations":53,"responsibleParty":72,"collaborators":11,"id":75,"slug":11,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":11,"eligibilityCriteria":79,"healthyVolunteers":76,"sex":80,"minAge":81,"maxAge":11,"enrollmentInfo":82,"targetDuration":11,"studyType":85,"phases":11,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":56,"whyStopped":11,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Hospital of Macerata","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":29,"otherOutcomes":11},[9,13,15,17,19,21,23,25,27],{"measure":10,"description":11,"timeFrame":12},"Overall Survival (OS) of patients with hormone\u002Fcastration-sensitive PC treated with ADT + ARSI or ADT + ARSI + docetaxel",null,"January 31h, 2024- May 31th, 2024",{"measure":14,"description":11,"timeFrame":12},"Progression-Free Survival of patients with hormone\u002Fcastration-sensitive PC treated with ADT + ARSI or ADT + ARSI + docetaxel",{"measure":16,"description":11,"timeFrame":12},"Overall Response Rate of patients with hormone\u002Fcastration-sensitive PC treated with ADT + ARSI or ADT + ARSI + docetaxel",{"measure":18,"description":11,"timeFrame":12},"Overall Survival (OS) of patients with castration resistant PC treated with Luthetium-177-PSMA therapy",{"measure":20,"description":11,"timeFrame":12},"Progression-Free Survival (PFS) of patients with castration resistant PC treated with Luthetium-177-PSMA therapy",{"measure":22,"description":11,"timeFrame":12},"Overall Response Rate (ORR) of patients with castration resistant PC treated with Luthetium-177-PSMA therapy",{"measure":24,"description":11,"timeFrame":12},"Overall Survival (OS) of patients with castration resistant PC treated with PARP inhibitors alone or in combined regimens",{"measure":26,"description":11,"timeFrame":12},"Progression-Free Survival (PFS) of patients with castration resistant PC treated with PARP inhibitors alone or in combined regimens",{"measure":28,"description":11,"timeFrame":12},"Overall Response Rate (ORR) of patients with castration resistant PC treated with PARP inhibitors alone or in combined regimens",[30,33],{"measure":31,"description":32,"timeFrame":12},"Time to progression of patients with different metastatic sites treated by the distinct combinations","Statistical analysis of data obtained by medical charts related to disease metastatic sites, treatment performed and period of time from the start of treatment until the radiological progression disease",{"measure":34,"description":35,"timeFrame":12},"prognostic role of lifestyle and concomitant medications","Statistical analysis of data obtained by medical charts related to lifestyle and concomitant medications",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":6,"timePerspective":37,"maskingInfo":11},"RETROSPECTIVE","treatment of patients with metastatic PCa. In the ARON-3 Study the investigators focused on three different settings:\n\n* ARON-3S: Patients with metachronous or de novo metastatic hormone\u002Fcastration-sensitive PCa treated with ADT + ARSI or ADT + ARSI + docetaxel\n* ARON-3Lu: Patients receiving Lutetium-177 PSMA for castration resistant PC (CRPC)\n* ARON-3GEN: Patients treated with PARP inhibitors (alone or plus ARSI) for CRPC",[40,43,45],{"label":41,"type":11,"description":42,"interventionNames":11},"For ARON-3S: Patients with metachronous or de novo metastatic hormone\u002Fcastration-sensitive PCa","Patients with metachronous or de novo metastatic hormone\u002Fcastration-sensitive PCa treated with ADT+ARSI or ADT+ARSI+docetaxel",{"label":44,"type":11,"description":11,"interventionNames":11},"For ARON-3Lu: Patients receiving Lutetium-177 PSMA for castration resistant PC (CRPC)",{"label":46,"type":11,"description":11,"interventionNames":11},"For ARON-3GEN: Patients treated with PARP inhibitors (alone or plus ARSI) for CRPC",[48],{"name":49,"role":50,"phone":51,"phoneExt":11,"email":52},"Matteo Santoni","CONTACT","+39 07332573752","sorgentoni.giulia@gmail.com",[54],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Ospedale di Macerata","RECRUITING","Province of Macerata","Macerata","62100","Italy","IT",{"type":63,"coordinates":64},"Point",[65,66],13.45293,43.29789,{"lat":66,"lon":65},[69],{"name":70,"role":50,"phone":71,"phoneExt":11,"email":52},"Matteo Santoni, MD, PhD","+3907332573752",{"type":73,"investigatorFullName":49,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Medical Doctor, Principal Investigator","100531496",false,"NCT06200558","ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa","Inclusion Criteria:\n\n* Patients aged \\>18y\n* Cytological or Histologically confirmed diagnosis of PC\n* Histologically or radiologically confirmed diagnosis of metastatic disease and\n\nFor ARON-3S\n\n▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)\n\nFor ARON-3Lu\n\n▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC\n\nFor ARON-3GEN\n\n* HRD POSITIVE STATUS\n* Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of PC\n* Patients without histologically or radiologically confirmed metastatic disease and\n\nFor ARON-3S\n\n▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section\n\nFor ARON-3Lu\n\n▪ Patients treated with Luthetium-177-PSMA therapy for hormone\u002Fcastration sensitive PC\n\nFor ARON-3GEN\n\n* HRD NEGATIVE STATUS\n* Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study","ALL","18 Years",{"count":83,"type":84},534,"ESTIMATED","OBSERVATIONAL","Study wants to explore real-world data in three distinct settings\n\n* Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \\_ARON-3S\n* Patients receiving Lutetium-177 PSMA for mCRPC \\_ ARON-3Lu\n* Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \\_ ARON-3GEN",[88],"Prostate Cancer",[90,91,92,93,94],"mCSPC","Lutetium-177 PSMA","PARP inhibitors","ADT","ARSI","2025-11-19",{"date":97,"type":98},"2025-11-26","ACTUAL",{"date":100,"type":98},"2024-01-31",{"date":102,"type":84},"2028-02-01",{"name":5,"class":6},1]